CDR-Life is a biotherapeutics company developing novel therapies harnessing the power of the immune system. Today’s cancer immunotherapies are powerful but are not tumor targeted, which compromises both efficacy and safety. We are developing a next generation of highly tumor-selective immunotherapies to truly empower the immune system to eradicate malignant cells without the off-tumor-related limitations of current immunotherapies.
CDR-Life has developed the unique M-gager® technology to generate MHC-specific antibody-based T cell engagers that target highly tumor-specific intracellular antigens with unparalleled specificity. Our dual-MHC binding molecule format based on antibody fragments has the promise of developing new immunotherapies with high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects.
CDR-Life is advancing a growing portfolio of novel and highly tumor-selective immunotherapies based on the M-gager® technology.
CDR-Life has developed the unique M-gager® technology to generate MHC-specific antibody-based T cell engagers that target highly tumor-specific intracellular antigens with unparalleled specificity. Our dual-MHC binding molecule format based on antibody fragments has the promise of developing new immunotherapies with high tumor cell killing potency, longer duration of effect, and lower risk of immune-related adverse effects.
CDR-Life is advancing a growing portfolio of novel and highly tumor-selective immunotherapies based on the M-gager® technology.
Location: Switzerland, Zurich, Schlieren
Employees: 11-50
Total raised: $76M
Founded date: 2017
Investors 3
| Date | Name | Website |
| 16.04.2022 | Jeito Capi... | jeito.life |
| 19.04.2022 | Omega Fund... | omegafunds... |
| 16.05.2022 | VentureLab | venturelab... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.04.2022 | Series A | $76M | Jeito Capi... |
Mentions in press and media 29
| Date | Title | Description |
| 16.09.2024 | Positive clinical progress in the biotech scene | With the dosing of its first patient for lead candidate CDR404, CDR-Life has made significant clinical progress in its M-gager® portfolio for solid tumors, marking important milestones in the company’s mission to deliver innovative, antibo... |
| 01.05.2024 | Triumphs and a setback in the biotech sector | The successful advancement of CDR-Life Inc.’s Phase 1 study with BI 771716, its therapeutic candidate in partnership with Boehringer Ingelheim (BI) for the treatment of geographic atrophy (GA), has triggered a milestone payment to the star... |
| 26.01.2024 | New milestones for life sciences startups | BioVersys AG is a clinical stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for life-threatening multidrug-resistant bacterial infections and targeted microbiome modulation. The company is d... |
| 14.12.2023 | CDR-Life advances into the clinical phase | |
| 03.08.2023 | CDR Life obtains milestone payment | |
| 02.09.2022 | Change of management in pursuit of growth | |
| 23.05.2022 | Swiss Biotechs display their innovations at BIO 2022 International Convention | |
| 14.04.2022 | Health tech fund raises $800 million as COVID speeds up change in the medical industry | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It was already well underway prior to COVID—the wave of innovation in health tech, that is. But n... |
| 13.04.2022 | CDR-Life Announces $76 Million Raised in Series A Funding | ZÜRICH, Switzerland, April 13, 2022 (GLOBE NEWSWIRE) -- CDR-Life Inc., a biotechnology company pioneering a new and differentiated class of highly tumor-specific immuno-oncology therapeutics based on its proprietary antibody-based MHC-targe... |
| 13.04.2022 | Swiss biotech CDR Life uses $76M series A funding round to ready T-cell engagers for clinic | Swiss biotech CDR Life has nabbed $76 million in series A bucks to flesh out its multispecific T-cell engagers, a fundraising haul led by Sanofi-backed, Paris investment firm Jeito Capital, which now turns its attention toward bolstering au... |
Show more